脾边缘区淋巴瘤的外科治疗
Surgical management of splenic marginal zone lymphoma.
作者信息
Kennedy N D, Lê G N, Kelly M E, Harding T, Fadalla K, Winter D C
机构信息
Department of Surgery, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
The National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.
出版信息
Ir J Med Sci. 2018 May;187(2):343-347. doi: 10.1007/s11845-017-1689-6. Epub 2017 Oct 17.
OBJECTIVES
Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell lymphoma with variable prognosis. As a result, there is sparse knowledge on the role of splenectomy and best management approaches. We aim to explore management strategies and outcomes amongst the cohort of SMZL patients at our centre.
METHOD
A retrospective review of all splenectomies performed at a tertiary referral unit over a 23-year period was assessed. Immunohistochemical and pathological results of splenic samples, bone marrow biopsies, and peripheral blood were compiled. Operative management, surgical, and survival outcomes were assessed. Prognostic stratifications were applied and survival rates were calculated.
RESULTS
Eight cases of SMZL from a database of 693 splenectomies were identified. All patients had intermediate/high-risk disease. All patients underwent splenectomy with one patient receiving preoperative rituximab. All patients had progression-free survival and resolution of disease.
CONCLUSION
Based on the data obtained, current practice requires defined guidelines and centralised care.
目的
脾边缘区淋巴瘤（SMZL）是一种罕见的惰性B细胞淋巴瘤，预后不一。因此，关于脾切除术的作用和最佳治疗方法的了解甚少。我们旨在探讨我们中心SMZL患者队列的治疗策略和结局。
方法
对一家三级转诊单位在23年期间进行的所有脾切除术进行回顾性评估。收集脾样本、骨髓活检和外周血的免疫组织化学和病理结果。评估手术治疗、手术和生存结局。应用预后分层并计算生存率。
结果
从693例脾切除术数据库中识别出8例SMZL患者。所有患者均患有中/高危疾病。所有患者均接受了脾切除术，其中1例患者术前接受了利妥昔单抗治疗。所有患者均无进展生存期且疾病得到缓解。
结论
根据获得的数据，目前的做法需要明确的指南和集中护理。
Zotero 插件